Dapoxetine hydrochloride for premature ejaculation - horizon scanning review
NHSC
Record ID 32005000242
English
Authors' objectives:
This study aims to assess the effectiveness of dapoxetine hydrochloride for premature ejaculation.
Authors' recommendations:
Dapoxetine hydrochloride (AP 38) is a selective serotonin reuptake inhibitor (SSRI) in phase III trials for the management of premature ejaculation (PE) in males of 18 years or older. Results from a placebo controlled, randomised, phase II trial in 130 heterosexual males show a significant increase in intravaginal ejaculatory time compared to placebo. US phase III trials are ongoing.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
http://www.hsric.nihr.ac.uk/search
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Ejaculation
- Selective Serotonin Reuptake Inhibitors
- Sexual Dysfunction, Physiological
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.